PL354110A1 - Combined therapy for treating the both alcoholism and alcohol dependence - Google Patents

Combined therapy for treating the both alcoholism and alcohol dependence

Info

Publication number
PL354110A1
PL354110A1 PL02354110A PL35411002A PL354110A1 PL 354110 A1 PL354110 A1 PL 354110A1 PL 02354110 A PL02354110 A PL 02354110A PL 35411002 A PL35411002 A PL 35411002A PL 354110 A1 PL354110 A1 PL 354110A1
Authority
PL
Poland
Prior art keywords
alcoholism
treating
combined therapy
alcohol dependence
dependence
Prior art date
Application number
PL02354110A
Other languages
English (en)
Inventor
Harry Ralph Howard Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL354110A1 publication Critical patent/PL354110A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL02354110A 2001-05-23 2002-05-23 Combined therapy for treating the both alcoholism and alcohol dependence PL354110A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29308801P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
PL354110A1 true PL354110A1 (en) 2002-12-02

Family

ID=23127615

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02354110A PL354110A1 (en) 2001-05-23 2002-05-23 Combined therapy for treating the both alcoholism and alcohol dependence

Country Status (11)

Country Link
US (2) US20030130322A1 (cg-RX-API-DMAC10.html)
EP (1) EP1262196A3 (cg-RX-API-DMAC10.html)
JP (1) JP2002370975A (cg-RX-API-DMAC10.html)
KR (1) KR20020090153A (cg-RX-API-DMAC10.html)
CN (1) CN1386503A (cg-RX-API-DMAC10.html)
AU (1) AU4068602A (cg-RX-API-DMAC10.html)
CA (1) CA2386740A1 (cg-RX-API-DMAC10.html)
HU (1) HUP0201722A2 (cg-RX-API-DMAC10.html)
NZ (1) NZ519032A (cg-RX-API-DMAC10.html)
PL (1) PL354110A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200204019B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4343948B2 (ja) 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
US8758443B2 (en) 2005-05-06 2014-06-24 Titan Spine, Llc Implants with integration surfaces having regular repeating surface patterns
DK2135603T3 (da) 2005-11-22 2013-03-25 Orexigen Therapeutics Inc Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
DE602007005402D1 (de) 2006-11-09 2010-04-29 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
WO2008077092A2 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
CA2716498C (en) 2008-02-28 2020-12-22 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
CA2804174A1 (en) 2010-07-02 2012-01-05 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
EP4629257A3 (en) 2012-06-06 2025-12-10 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
CN114588467B (zh) * 2022-04-01 2022-11-29 广州蓝仕威克医疗科技有限公司 一种基于气体混合比例供气解决酒精中毒的方法及呼吸机
CN115671107B (zh) * 2022-12-29 2023-04-04 文韬创新药物研究（北京）有限责任公司 用于解酒的复方药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
EP0782445B1 (en) * 1994-09-19 2002-03-13 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
WO2000050380A1 (en) * 1999-02-23 2000-08-31 Pfizer Products Inc. Monoamine reuptake inhibitors for treatment of cns disorders
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
HK1047577B (zh) * 1999-10-13 2005-09-16 辉瑞产品公司 用作一元胺重摄取抑制剂的联芳醚衍生物

Also Published As

Publication number Publication date
CN1386503A (zh) 2002-12-25
US20040162316A1 (en) 2004-08-19
ZA200204019B (en) 2003-11-21
HU0201722D0 (cg-RX-API-DMAC10.html) 2002-07-29
HUP0201722A2 (hu) 2003-07-28
NZ519032A (en) 2003-10-31
EP1262196A3 (en) 2002-12-18
EP1262196A2 (en) 2002-12-04
AU4068602A (en) 2002-12-05
JP2002370975A (ja) 2002-12-24
US20030130322A1 (en) 2003-07-10
KR20020090153A (ko) 2002-11-30
CA2386740A1 (en) 2002-11-23

Similar Documents

Publication Publication Date Title
EP1463438A4 (en) ENDOMURAL THERAPY
GB0028429D0 (en) Therapy
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
GB0126879D0 (en) Combination therapy
PL354110A1 (en) Combined therapy for treating the both alcoholism and alcohol dependence
EP1434772A4 (en) CONNECTIONS AND METHODS
GB0118383D0 (en) Therapeutic methods
GB0126889D0 (en) Compounds and their uses
GB2389532C (en) The method of treating cancer
AU2002359694A8 (en) Compounds and methods
GB0111496D0 (en) Therapeutic systems and methods
GB0101933D0 (en) Therapy
GB0108485D0 (en) Combination therapy
GB0119025D0 (en) Compounds and their therapeutic use
AU2002335667A1 (en) Modified reoviral therapy
GB0127384D0 (en) Well treatment system
HU0200253D0 (en) Combination therapy
PL354111A1 (en) Combined therapy for treating the both depression and anxiety
EP1379240A4 (en) CONNECTIONS AND METHODS
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
IL149703A0 (en) Combination treatment for alcoholism and alcohol dependence
AU6884801A (en) Therapeutic compounds and methods
GB0108817D0 (en) Therapy
GB0108816D0 (en) Therapy

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)